A novel plasma based early colorectal cancer screening assay base on methylated SDC2 and SFRP2
- 1 April 2020
- journal article
- research article
- Published by Elsevier BV in Clinica Chimica Acta; International Journal of Clinical Chemistry
- Vol. 503, 84-89
- https://doi.org/10.1016/j.cca.2020.01.010
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81827901, 61850410528)
- Jiangsu Province (BE2019688)
This publication has 31 references indexed in Scilit:
- Colorectal cancer screening: a global overview of existing programmesGut, 2015
- Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to knowGut, 2015
- Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomasWorld Journal of Gastroenterology, 2015
- Validation of a Real-Time PCR–Based Qualitative Assay for the Detection of Methylated SEPT9 DNA in Human PlasmaClinical Chemistry, 2014
- Strategies for expanding colorectal cancer screening at community health centersCA: A Cancer Journal for Clinicians, 2013
- Genome-Wide Identification and Validation of a Novel Methylation Biomarker, SDC2, for Blood-Based Detection of Colorectal CancerThe Journal of Molecular Diagnostics, 2013
- Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancerInternational Journal of Cancer, 2012
- Trends in Colorectal Cancer Incidence Rates in the United States by Tumor Location and Stage, 1992–2008Cancer Epidemiology, Biomarkers & Prevention, 2012
- Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screeningWorld Journal of Gastroenterology, 2008
- SFRP2 methylation in fecal DNA—a marker for colorectal polypsInternational Journal of Colorectal Disease, 2007